retatrutide los angeles Peptide Therapy Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Weight trajectories, metabolic markers, and subjective wellbeing measurements provide optimization guidance

Regenerative Renewal

Amy Schroeder Principal Research Scientist | July 9, 2025 Current Landscape Overview Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging drug class that are mostly indicated to improve glycemic control in patients with type 2 diabetes mellitus (T2D) and reduce body weight

a , b , c

Future research should focus on integrating polygenic risk scores with environmental exposure metricssuch as long-term PM2.5 levels, radon, and occupational chemicalsto quantify cumulative disease risk